Vaximm Ag

Calculating rank

USPTO Granted Patents = 9

% Expired Patents = 11.1

EPO Patents = 5

Forward Citations = 28

Loading Chart...

4 inventors (with patents filed for the assignee):

Heinz Lubenau (9 out of 15 patents)

Marco Springer (3 out of 4 patents)

Holger Siede (1 out of 1 patent)

4. Renate Janssen (1 out of 1 patent)

9 patents: Sort by Forward Citations

1. 11357842 - PD-L1 targeting DNA vaccine for cancer immunotherapy (2022-06-14),

2. 10980868 - VEGFR-2 targeting immunotherapy approach (2021-04-20),

3. 10905752 - VEGFR-2 targeting DNA vaccine for combination therapy (2021-02-02),

4. 10821163 - Process for the production of a DNA vaccine for cancer immunotherapy (2020-11-03),

5. 10815455 - Salmonella-based vectors for cancer immunotherapy targeting Wilms' tumor gene WT1 (2020-10-27),

6. 10293037 - DNA vaccine for use in pancreatic cancer patients (2019-05-21),

7. 9920297 - [object Object] (2018-03-20),

8. 9493738 - [object Object] (2016-11-15),

9. 9415098 - DNA vaccine for use in pancreatic cancer patients (2016-08-16),

Company Overview

Vaximm Ag is a clinical-stage biotechnology company that focuses on developing oral T-cell immunotherapies for patients suffering from cancer. The company's lead product candidate, VXM01, is designed to stimulate the patient's immune system to attack tumor cells. Vaximm's innovative approach to cancer treatment has shown promising results in clinical trials, making it a pioneering player in the field of immunotherapy.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Nov 3 2026

9 Patents

#41 in Basel

#1,128 in Switzerland

Basel, Switzerland

Vaximm Ag

Forward Citations = 28

4 inventors:

Heinz Lubenau (9 out of 15 patents)

Marco Springer (3 out of 4 patents)

Holger Siede (1 out of 1 patent)

4. Renate Janssen (1 out of 1 patent)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Vaximm Ag. Retrieved from https://idiyas.com/company/vaximm-ag

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

5 patents (EPO):

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]